Reader Comments
Post a new comment on this article
Post Your Discussion Comment
Please follow our guidelines for comments and review our competing interests policy. Comments that do not conform to our guidelines will be promptly removed and the user account disabled. The following must be avoided:
- Remarks that could be interpreted as allegations of misconduct
- Unsupported assertions or statements
- Inflammatory or insulting language
Thank You!
Thank you for taking the time to flag this posting; we review flagged postings on a regular basis.
closeAnti-EphB2 autoantibody
Posted by tshirai on 20 Sep 2016 at 09:56 GMT
Dear Authors,
We read this article with great interest because we had also reported anti-EphB2 autoantibody in an SLE patient who manifested acute necrotizing encephalopathy [1]. We have been trying to identify autoantigens expressed on the cell surface, and had established the SARF method using retroviral vector and flow cytometry [2]. The anti-EphB2 autoantibody from the patient reacted with the extracellular domain of EphB2, which was confirmed by flow cytometry. We had measured autoantibodies against extracellular domain of EphB2 in 47 SLE patients, but none of them showed binding activity to the extracellular domain of EphB2 [1]. Therefore, we speculated that anti-EphB2 antibody had potential to induce vascular lesion in the acute necrotizing encephalopathy.
In this article, authors utilized ProtoArray analysis and showed that anti-EphB2 autoantibodies were detected in 56 % of SLE patients, and most of them recognized the intracytoplasmic region of EphB2. Furthermore, they revealed that 34% of SSc patients also possessed anti-EphB2 autoantibodies. These data are pretty exciting and we would like to know whether these patients have anti-EphB2 autoantibodies against extracellular domain because such autoantibodies can directly induce vascular inflammation.
Thanks,
Tsuyoshi Shirai MD. PhD.
Hiroshi Fujii MD. PhD.
Department of Hematology & Rheumatology,
Tohoku University Graduate School of Medicine, Japan
1. Shirai, T., H. Fujii, M. Ono, R. Watanabe, Y. Shirota, S. Saito, T. Ishii, M. Nose, and H. Harigae. A Novel Autoantibody against Ephrin Type B Receptor 2 in Acute Necrotizing Encephalopathy. Journal of Neuroinflammation. 2013;(10): 128. doi: 10.1186/1742-2094-10-128.
2. Shirai, T., H. Fujii, M. Ono, R. Watanabe, T. Ishii, and H. Harigae. An Innovative Method to Identify Autoantigens Expressed on the Endothelial Cell Surface: Serological Identification System for Autoantigens Using a Retroviral Vector and Flow Cytometry (SARF). Clinical Developmental Immunology. 2013; (2013): 453058. doi: 10.1155/2013/453058.
RE: Anti-EphB2 autoantibody
natlambert replied to tshirai on 13 Oct 2016 at 11:36 GMT
Dear colleagues,
We are glad you found our recently published results exciting [1]. We also read with a great interest your paper reporting anti-EphB2 autoantibodies (AAb) in a patient with neuropsychiatric Systemic Lupus Erythematosus (SLE) who manifested acute necrotizing encephalopathy [2]. We did not mention your work in our manuscript precisely because your work was relative to AAb recognizing the extracellular domain of EphB2. In our study, all the patients with SLE who had anti-EphB2 AAb had them recognizing the intracytoplasmic region of EphB2 and precisely the tyrosine kinase domain.
Indeed on the version 5.0 of Invitrogen Human protein microarrays (Invitrogen, Carlsbad, CA, USA), the 3 proteins spotted on the nitrocellulose-coated glass slide called “Ephrin type-B receptor 2”, represented only the tyrosine kinase domain more or less truncated (see www.thermofisher.com for protein content list 5.0). Therefore we have never tested whether our sera samples have AAb against the EphB2 extracellular domain. We agree that it would be very informative to do it.
On the other hand, we would be very curious to know whether the 47 sera from Japanese patients with SLE, previously tested in your study for their binding activity to the extracellular domain of EphB2 and found negative, would be positive for AAb against the tyrosine kinase domain of EphB2 and particularly against the peptide 7 we describe as being the major epitope in Lupus.
Thank you for your interest in our research.
Yours faithfully,
N.C. Lambert, PhD
INSERM UMRs 1097, Marseille Luminy, France
1. Azzouz DF, Martin GV, Arnoux F, Balandraud N, Martin T, Dubucquoi S, et al. Anti-Ephrin Type-B Receptor 2 (EphB2) and Anti-Three Prime Histone mRNA EXonuclease 1 (THEX1) Autoantibodies in Scleroderma and Lupus. PloS one. 2016;11(9):e0160283. doi: 10.1371/journal.pone.0160283. PubMed PMID: 27617966.
2. Shirai T, Fujii H, Ono M, Watanabe R, Shirota Y, Saito S, et al. A novel autoantibody against ephrin type B receptor 2 in acute necrotizing encephalopathy. J Neuroinflammation. 2013;10:128. doi: 10.1186/1742-2094-10-128. PubMed PMID: 24139226; PubMed Central PMCID: PMCPMC3853009.